1 PROGRESS was a phase 3, parallel-group,
multicentre,
96-week study of patients who completed TRA
2 The ARIA study is a randomised, open-label,
multicentre,
active-controlled, parallel-group, non-infe
3 We did this double-blind,
multicentre,
active-controlled, randomised controlled no
4 ed sera of 148 children participating in the
Multicentre Allergy Study, a birth cohort born in 1990.
5 In the randomised, controlled,
multicentre,
AML17 trial, eligible patients (aged >/=16
6 Large
multicentre and prospective studies are warranted to fur
7 DS Project: an international, collaborative,
multicentre,
and multidisciplinary project which aimed t
8 childhood asthma risk were evaluated in the
Multicentre Asthma Genetics in Childhood Study (MAGICS)/
9 ized trial comparing the 2 procedures (Swiss
Multicentre Bypass Or Sleeve Study; SM-BOSS).
10 Therefore, we designed the
multicentre ChroPac trial to investigate the long-term o
11 ontrolled, single-blind, parallel two-group,
multicentre clinical trial.
12 ndomized, double-masked, placebo-controlled,
multicentre clinical trial.
13 Using databases from two
multicentre clinical trials, patients were retrospective
14 Building on these findings, a
multicentre,
cluster randomised controlled trial is plan
15 We aimed to assess whether a
multicentre,
cluster randomised trial is a feasible meth
16 METHODS AND FINDING:
Multicentre,
cluster-randomised controlled trial with ra
17 ing Young Lives in Europe (SEYLE) study is a
multicentre,
cluster-randomised controlled trial.
18 An international
multicentre cohort analysis of outpatients with bronchie
19 ailability was retrospectively analysed in a
multicentre cohort of 934 anaemic patients at 4 UK hospi
20 for multiple sclerosis diagnosis in a large
multicentre cohort of patients with CIS to provide evide
21 t the long-term outcome based on the largest
multicentre cohort of patients with orthostatic tremor.
22 In this
multicentre cohort study (BEST2), patients with Barrett'
23 PRICOT study was a prospective observational
multicentre cohort study of children from birth to 15 ye
24 A prospective
multicentre cohort study of EVD insertions in 21 neurosu
25 We performed a
multicentre cohort study of the Parkinson's Progression
26 ive HIV Cohort (UK CHIC) Study is an ongoing
multicentre cohort study that brings together in a stand
27 We carried out a
multicentre cohort study using data from 19 obstetric un
28 A
multicentre cohort study was held in Morocco, designed t
29 similar patients studied in a North American
multicentre cohort.
30 We did this retrospective,
multicentre,
cohort study using routine lower gastrointe
31 In this
multicentre,
cohort study, we collected data about patie
32 alisation, multidisciplinary management, and
multicentre collaboration in research; similarly robust
33 reated lymph node-negative cohort (n=684), a
multicentre combined cohort (n=5439), the Nottingham his
34 This was a phase 3, double-blind, global
multicentre,
comparative-group study.
35 Through coordinated
multicentre consortia, these genomic approaches are like
36 is rater-independent and could be used in a
multicentre context, as it is simple, rapid and fully au
37 tion of the mesoscale variability measure to
multicentre datasets of three mental disorders and match
38 In this prospective,
multicentre,
diagnostic accuracy study, we recruited adu
39 This phase 1b, open-label,
multicentre,
dose-escalation study was done at six hospi
40 In INFORMS, a
multicentre,
double-blind, placebo-controlled parallel-g
41 ed as a sublingual tablet were assessed in a
multicentre,
double-blind, placebo-controlled study cond
42 For this international,
multicentre,
double-blind, placebo-controlled trial, adu
43 We did a
multicentre,
double-blind, placebo-controlled, parallel
44 In this
multicentre,
double-blind, randomised phase 3 study, wom
45 This was a
multicentre,
double-blind, randomised placebo-controlled
46 In this
multicentre,
double-blind, randomised trial in seven Dan
47 DURATION-8 was a 28 week,
multicentre,
double-blind, randomised, active-controlled
48 In this
multicentre,
double-blind, randomised, controlled, phase
49 In this
multicentre,
double-blind, randomised, placebo-controlle
50 This international,
multicentre,
double-blind, randomised, placebo-controlle
51 We did this
multicentre,
double-blind, randomised, placebo-controlle
52 We did a
multicentre,
double-blind, randomised, placebo-controlle
53 Vitamin D Osteoporosis Study (MAVIDOS) was a
multicentre,
double-blind, randomised, placebo-controlle
54 This
multicentre,
double-blinded, randomised, placebo-control
55 We did this
multicentre,
double-masked, randomised, placebo-controll
56 th processing and analysis of multiplatform,
multicentre DTI data, and effectively demonstrates the a
57 We did a
multicentre evaluation of clinical data of patients who
58 In the
multicentre EXAMINATION trial, done in Italy, Spain, and
59 Here we present the results of a
multicentre,
external validation of the AVICH score.
60 o and offer some advantages over traditional
multicentre field trials for evaluation of novel therape
61 risk of sporadic BAVM in the international,
multicentre Genetics of Arteriovenous Malformation (GEN-
62 ive data from 1605 children treated in eight
multicentre hepatoblastoma trials over 25 years.
63 the randomised, double-blind, double-dummy,
multicentre,
Hokusai-VTE trial done between Jan 28, 2010
64 The PROTECT
multicentre inception cohort study was based at 29 centr
65 patients with a 4-year follow-up tested in a
multicentre international longitudinal study of de novo
66 ith Surgical Treatments [PODCAST] study is a
multicentre,
international randomised trial that enrolle
67 In this open-label, phase 3,
multicentre,
international study, adults with relapsed o
68 This
multicentre,
international, open-label, exploratory, ran
69 from primary or specialty care clinics in a
multicentre,
international, open-label, randomised, pros
70 We did a
multicentre,
international, open-label, single-arm study
71 We did a
multicentre,
international, parallel-group, assessor-bli
72 tion in venous thromboembolism (XALIA) was a
multicentre,
international, prospective, non-interventio
73 In this
multicentre,
international, prospective, single-group, o
74 We did a
multicentre,
international, randomised clinical trial at
75 In this
multicentre,
international, randomised, open-label, phas
76 SPYRAL HTN-OFF MED was a
multicentre,
international, single-blind, randomised, sh
77 The SCLC cohort of this phase 1/2
multicentre,
multi-arm, open-label trial was conducted a
78 This ongoing,
multicentre,
multicohort, open-label, phase 2 study eval
79 We did a
multicentre,
multicountry, retrospective observational c
80 open-label, non-inferiority, parallel-group,
multicentre,
multinational, phase 3a trial (SUSTAIN 4) a
81 We did a
multicentre,
multinational, retrospective cohort study u
82 In this single-blind, randomised,
multicentre,
non-inferiority trial (Shockless IMPLant Ev
83 We did this prospective,
multicentre,
non-randomised, first-in-man trial at 13 pe
84 We did a prospective,
multicentre,
non-randomised, open-label intervention stu
85 phase 2, sequentially enrolled, multicohort,
multicentre,
non-randomised, open-label study, adults (>
86 In this phase 2,
multicentre,
non-randomised, open-label study, we enroll
87 In this phase 2,
multicentre,
non-randomised, open-label study, we enroll
88 We did a
multicentre,
non-randomised, open-label, phase 1b study
89 s in another dataset from a cross-sectional,
multicentre observational study (the 3B study) of outpat
90 We did a
multicentre observational study analysing comprehensive
91 We did a
multicentre open-label randomised controlled trial in te
92 In this
multicentre,
open-label randomised trial, 102 hospitals
93 In this phase 1/2,
multicentre,
open-label study, we enrolled patients (age
94 This
multicentre,
open-label substudy was done at 19 sites in
95 We did a phase 1/2,
multicentre,
open-label trial (MUK six) at four hospital
96 In this
multicentre,
open-label trial, adult patients with histo
97 Part A of these phase 2, randomised,
multicentre,
open-label, clinical trials enrolled partic
98 We did this randomised,
multicentre,
open-label, dose-escalation study (1703) at
99 In this phase 2,
multicentre,
open-label, dose-finding study (PACE-MDS),
100 We did this
multicentre,
open-label, masked-endpoint, randomised tri
101 In this randomised, actively controlled,
multicentre,
open-label, non-inferiority trial, we recru
102 In this interim analysis of a
multicentre,
open-label, non-randomised, phase 2 trial,
103 This
multicentre,
open-label, parallel group, randomised cont
104 In this
multicentre,
open-label, phase 1 study, patients from ni
105 In this dose-expansion cohort of a
multicentre,
open-label, phase 1 study, patients with pr
106 This study was a
multicentre,
open-label, phase 1b trial done at 13 cance
107 In this
multicentre,
open-label, phase 2 randomised trial in hos
108 In this ongoing,
multicentre,
open-label, phase 2 trial, we enrolled adul
109 We conducted this
multicentre,
open-label, phase 3 randomised controlled t
110 HERA (BIG 1-01) is an international,
multicentre,
open-label, phase 3 randomised trial of 510
111 Kids B-LONG was a
multicentre,
open-label, phase 3 study assessing the saf
112 We did a
multicentre,
open-label, phase 3, randomised controlled
113 n's INterval Appendicectomy (CHINA) study, a
multicentre,
open-label, randomised controlled study at
114 We did a phase 3,
multicentre,
open-label, randomised controlled trial at
115 We did a pragmatic,
multicentre,
open-label, randomised controlled trial in
116 We undertook this
multicentre,
open-label, randomised controlled trial in
117 In this
multicentre,
open-label, randomised controlled trial, we
118 The
multicentre,
open-label, randomised phase 3 GOG-0213 tri
119 SYNERGY was a phase 3,
multicentre,
open-label, randomised trial set at 134 stu
120 This
multicentre,
open-label, randomised, controlled phase 2
121 The TEAM trial, a
multicentre,
open-label, randomised, controlled, phase 3
122 PORTEC-3 was a
multicentre,
open-label, randomised, international trial
123 We did the
multicentre,
open-label, randomised, parallel, phase 3 S
124 In this
multicentre,
open-label, randomised, phase 3 trial, we r
125 In this international
multicentre,
open-label, single-arm, first-in-man phase
126 We did a
multicentre,
open-label, single-arm, phase 3b study (GAR
127 We did this
multicentre,
paired-cohort, confirmatory study to test d
128 In this
multicentre,
parallel group, randomised controlled trial
129 In this
multicentre,
parallel group, superiority, open-label, bl
130 We did a pragmatic,
multicentre,
parallel-group randomised controlled trial
131 We did this pragmatic,
multicentre,
parallel-group, observer-blind, randomised
132 The eTHoS trial was a large, open-label,
multicentre,
parallel-group, pragmatic randomised contro
133 We did this
multicentre,
parallel-group, randomised controlled trial
134 In a prospective, double-blind,
multicentre,
parallel-group, randomised trial, we enroll
135 For the
multicentre,
parallel-group, randomised, controlled, ope
136 In a
multicentre phase 1-2 study, patients (aged </=65 years)
137 In this
multicentre phase 1b trial, we recruited patients aged 1
138 In this
multicentre phase 1b, first-in-human, single-blind, plac
139 cohort (MD Anderson-NeoACT; n=508), and the
multicentre phase 2 neoadjuvant clinical trial cohort (p
140 We did a randomised, double-blind,
multicentre phase 2 trial of a combination of oseltamivi
141 In this open-label, single group,
multicentre phase 2 trial, we recruited HIV-negative adu
142 We did this single-arm, open-label,
multicentre phase 3 study at 40 sites in Belgium, Canada
143 In this controlled, double-blind,
multicentre phase 3 study, we recruited virologically su
144 This open-label,
multicentre,
phase 1 study was undertaken at 11 centres
145 andomised, double-blind, placebo-controlled,
multicentre,
phase 1B study, patients were randomly assi
146 This study was an open-label,
multicentre,
phase 1b trial of patients with recurrent o
147 For this single-arm,
multicentre,
phase 2 study, in 47 academic medical centr
148 We did this single-arm,
multicentre,
phase 2 trial at ten academic centres in th
149 In this open-label,
multicentre,
phase 2 trial done in Canada, Spain, and th
150 e group, randomised, controlled, open-label,
multicentre,
phase 2 trial was done in 37 academic and c
151 In this randomised, open-label,
multicentre,
phase 2 trial, 29 academic medical centres
152 In this
multicentre,
phase 2, single-arm study, patients aged 18
153 This randomised, open-label,
multicentre,
phase 3 clinical trial enrolled patients wi
154 We did a randomised, single-blind,
multicentre,
phase 3 study (DESSOLVE III) at 20 hospital
155 andomised, double-blind, placebo-controlled,
multicentre,
phase 3 study.
156 andomised, placebo-controlled, double-blind,
multicentre,
phase 3 trial (REACH), patients were enroll
157 This randomised, double-blind,
multicentre,
phase 3 trial was done in 87 centres in 21
158 In this
multicentre,
phase 3, randomised, controlled trial, we e
159 TWiTCH was a
multicentre,
phase 3, randomised, open-label, non-inferi
160 e-blind, placebo-controlled, parallel group,
multicentre,
phase 3-4 trial, the Roflumilast and Exacer
161 e-blind, placebo-controlled, parallel-group,
multicentre,
phase 3b trial (MUSCA) in 146 hospitals or
162 PETIT was a three-part, randomised,
multicentre,
placebo-controlled study done at 22 centres
163 In this randomised, double-blind,
multicentre,
placebo-controlled, non-inferiority trial,
164 In this randomised, double-blind,
multicentre,
placebo-controlled, non-inferiority trial,
165 In this
multicentre,
placebo-controlled, randomised phase 2 stud
166 We did a double-blind,
multicentre,
placebo-controlled, randomised withdrawal p
167 No
multicentre population-based study powered to detect cha
168 We did this
multicentre,
pragmatic, observer-blind, randomised contr
169 We did a double-blind,
multicentre,
pragmatic, parallel-group, randomised contr
170 In this open-label,
multicentre,
pragmatic, randomised controlled trial, we
171 331 patients were selected from a
multicentre prospective cohort (160 treated with adalimu
172 Multicentre prospective double blind randomized controll
173 t onset of ventilation) is an international,
multicentre,
prospective study undertaken at 119 ICUs in
174 We did a
multicentre,
prospective, cohort study in the UK, at 16
175 In the FIRES
multicentre,
prospective, cohort study patients with cli
176 We did a
multicentre,
prospective, observational, cohort study of
177 In this
multicentre,
prospective, observational, first-in-man st
178 of the INTERACT CT substudies-international,
multicentre,
prospective, open, blinded end point, rando
179 We did a
multicentre,
prospective, open-label, non-inferiority ra
180 We enrolled patients in this open-label,
multicentre,
prospective, randomised, controlled trial b
181 We did an investigator-initiated,
multicentre,
prospective, randomised, open-label, blinde
182 We did a
multicentre,
prospective, randomised, open-label, blinde
183 pooled at a single-patient level from eight
multicentre randomised clinical trials with independent
184 The PPROMT trial was a
multicentre randomised controlled trial done at 65 centr
185 We conducted a 3-arm,
multicentre randomised controlled trial in primary- and
186 This
multicentre randomised controlled trial included patient
187 In this
multicentre randomised trial (UK Flexible Sigmoidoscopy
188 ORBITA is a blinded,
multicentre randomised trial of PCI versus a placebo pro
189 We did a phase 3, two-group, open-label,
multicentre,
randomised clinical trial at 92 hospitals i
190 In this
multicentre,
randomised controlled phase 3 study (the Pi
191 We did a
multicentre,
randomised controlled trial in eight hospit
192 We did this
multicentre,
randomised controlled trial in ten tertiary
193 cell Management (INFORM) trial, a pragmatic,
multicentre,
randomised controlled trial of patients (>/
194 This study was a pragmatic,
multicentre,
randomised controlled trial with participan
195 In this
multicentre,
randomised controlled trial, 75 adults with
196 We did two pragmatic, parallel-group,
multicentre,
randomised controlled trials for our study
197 This open-label,
multicentre,
randomised phase 3 study enrolled patients
198 ncer (ViP) trial was a phase 2 double-blind,
multicentre,
randomised placebo-controlled trial in prev
199 In a double-blind,
multicentre,
randomised placebo-controlled trial, we rec
200 In this double-blind,
multicentre,
randomised trial (GEMINI-ACS-1) done at 371
201 ny, Poland, and the USA in this prospective,
multicentre,
randomised trial.
202 Thrombectomy Evaluation (PISTE) trial was a
multicentre,
randomised, controlled clinical trial compa
203 In this
multicentre,
randomised, controlled, phase 2 study, elig
204 IMPORT LOW is a
multicentre,
randomised, controlled, phase 3, non-inferi
205 AMBITION was a
multicentre,
randomised, double-blind study, in which tr
206 In this
multicentre,
randomised, double-blind, controlled trial,
207 We did a 2-year,
multicentre,
randomised, double-blind, double-dummy, str
208 BOLT is an ongoing
multicentre,
randomised, double-blind, phase 2 trial.
209 We did this prospective,
multicentre,
randomised, double-blind, placebo-controlle
210 We did this
multicentre,
randomised, double-blind, placebo-controlle
211 RADIANT-4 is a
multicentre,
randomised, double-blind, placebo-controlle
212 We conducted this phase 2,
multicentre,
randomised, double-blind, placebo-controlle
213 In this
multicentre,
randomised, double-blind, placebo-controlle
214 reviously reported the interim analysis of a
multicentre,
randomised, double-blind, placebo-controlle
215 In this
multicentre,
randomised, double-blind, placebo-controlle
216 In our
multicentre,
randomised, double-blind, placebo-controlle
217 We did this
multicentre,
randomised, double-blind, placebo-controlle
218 In the
multicentre,
randomised, double-blind, placebo-controlle
219 In this
multicentre,
randomised, double-blind, placebo-controlle
220 This
multicentre,
randomised, double-blind, placebo-controlle
221 In this
multicentre,
randomised, open-label phase 2-3 trial, we
222 In this
multicentre,
randomised, open-label phase 3 trial (AGATE
223 We did a
multicentre,
randomised, open-label, phase 1/2 study of
224 LUNA was a prospective,
multicentre,
randomised, open-label, phase 2 trial of ad
225 In this international,
multicentre,
randomised, open-label, phase 3 study, we e
226 BSBMT/UKMF Myeloma X was a
multicentre,
randomised, open-label, phase 3 trial done
227 ACCL0431 was a
multicentre,
randomised, open-label, phase 3 trial that
228 In this
multicentre,
randomised, parallel-group study in 11 ECT
229 We performed this
multicentre,
randomised, parallel-group, double-blind, p
230 This international,
multicentre,
randomised, phase 3 trial (PERSIST-1) was d
231 In this phase 3,
multicentre,
randomised, placebo-controlled study, we ra
232 ain Alzheimer Preventive Trial was a 3-year,
multicentre,
randomised, placebo-controlled superiority
233 We did this
multicentre,
randomised, placebo-controlled trial in fou
234 We did this
multicentre,
randomised, placebo-controlled, double-blin
235 In this double-blind,
multicentre,
randomised, placebo-controlled, phase 3 stu
236 We did a
multicentre,
randomised, placebo-controlled, phase 3 tri
237 We did a
multicentre,
randomised, pragmatic, parallel group, plac
238 This
multicentre randomized study compared circumferential pu
239 We conducted a parallel-group,
multicentre,
randomized double-blind controlled trial of
240 Multicentre RCTs with standardized protocols conducted o
241 To address this concern, we developed a
multicentre registry (Pediatric Difficult Intubation [Pe
242 In this
multicentre,
retrospective analysis, we investigated gen
243 In a large
multicentre sample of cognitively normal subjects, as a
244 nalysis of data from the NLST, a randomised,
multicentre screening trial comparing three annual low-d
245 eriority for DPPHR were not confirmed in the
multicentre setting.
246 In this international,
multicentre,
single-arm, phase 1-2 trial, eligible patie
247 This US-based,
multicentre,
single-arm, phase 2 prevention study enroll
248 In this
multicentre,
single-arm, phase 2 study (KEYNOTE-052), ci
249 We did this open-label,
multicentre,
single-arm, phase 2 trial at five hospitals
250 BELIEF was an international,
multicentre,
single-arm, phase 2 trial done at 29 centre
251 For this
multicentre,
single-arm, two-cohort, phase 2 trial, pati
252 We did a
multicentre,
single-blind, patient-level, parallel, rand
253 We did a
multicentre,
single-blind, randomised, controlled trial
254 We did a
multicentre,
single-blinded, randomised controlled trial
255 e-blind, parallel-group, placebo-controlled,
multicentre studies done in outpatient clinics in Asia,
256 Findings from large
multicentre studies highlight that shifts of 12h or long
257 A prospective, non-interventional,
multicentre study (ICARUS (Impulse Control disorders And
258 andomised, double-blind, placebo-controlled,
multicentre study (REGAIN) in 76 hospitals and specialis
259 e-blind, placebo-controlled, parallel-group,
multicentre study at 183 hospitals and private rheumatol
260 This is a
multicentre study done at 11 paediatric MS centres in th
261 ed, parallel-controlled, three-arm, phase 3,
multicentre study done at 143 sites in 17 countries.
262 Troviral Treatment Enabling (LATTE) trial, a
multicentre study done in Canada and the USA, antiretrov
263 This
multicentre study involved four European reference labor
264 We report the results of a
multicentre study of aquaporin (AQP) 4 antibody (AQP4-Ab
265 We did an international,
multicentre study of community-dwelling, adult patients
266 andomised, double-blind, placebo-controlled,
multicentre study of erenumab for adults aged 18-65 year
267 ing data for five hospitals derived from the
Multicentre Study of Self-Harm in England (Jan 1, 2011,
268 This
multicentre study tested previously reported criteria of
269 was a prospective, parallel, single-blinded,
multicentre study that enrolled participants with New Yo
270 A
multicentre study was undertaken to assess structural co
271 In a pilot
multicentre study, 29 egg allergic patients (aged 1-5.5
272 ouble-blind, randomised, placebo-controlled,
multicentre study, adult patients (aged >/=18 years) wit
273 le-arm, open-label, non-randomised, phase 2,
multicentre study, done at 31 sites in nine countries, e
274 andomised, double-blind, placebo-controlled,
multicentre study, patients were enrolled at 54 hospital
275 In this randomised, phase 3, open-label,
multicentre study, patients with relapsed or refractory
276 In a
multicentre study, we analysed specific IgE to cashew ex
277 In this
multicentre study, we have performed detailed clinical a
278 In this phase 2, single-arm,
multicentre study, we recruited patients aged 18 years a
279 In our non-randomised phase 2, open-label,
multicentre study, we recruited pregnant women attending
280 ft Rejection (GoCAR) study is a prospective,
multicentre study.
281 andomised, double-blind, placebo-controlled,
multicentre study.
282 We did a randomised,
multicentre,
superiority trial comparing transradial aga
283 a randomised, open-label, active-controlled,
multicentre,
superiority trial to compare REG1 with biva
284 k (December 2014-February 2015) prospective,
multicentre survey of consecutive AF patients.
285 d, controlled, double-blind, parallel-group,
multicentre trial (11 sites in Finland, Germany, the Net
286 ernational, open-label, randomised, phase 3,
multicentre trial (TH CR-406/SARC021) at 81 academic or
287 We did a randomised, phase 2, open-label,
multicentre trial at 37 centres in five countries and en
288 The FAME study was a
multicentre trial done in Belgium, Denmark, Germany, the
289 A
multicentre trial evaluated the dose-response and tolera
290 We did a randomised, open-label
multicentre trial in 59 hospitals--57 in the UK, one in
291 This open-label randomised controlled
multicentre trial was part of a larger study.
292 ctive-controlled, open-label, international,
multicentre trial, done at 106 sites across nine countri
293 ernational, open-label, randomised, phase 3,
multicentre trial, we enrolled adult patients with CD30-
294 ve, randomized, blinded, placebo controlled,
multicentre trial.
295 Multicentre trials contradicted the benefits of tight co
296 ng cooperation and collaboration to complete
multicentre trials that advance knowledge and patient ca
297 ARIEL2 is an international,
multicentre,
two-part, phase 2, open-label study done at
298 The
multicentre-
validated AVICH score predicts clinical outc
299 In the
multicentre validation set, scores were 8% (95% CI 3-16)
300 re week in trial length; 1.32, 1.11-1.57 for
multicentre vs single-centre trials).